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Background and Objective. The features of asthma are airway inﬂammation, reversible airﬂow obstruction, and an increased
sensitivity to bronchoconstricting agents, termed airway hyperresponsiveness (AHR), excess production of Th2 cytokines, and
eosinophilaccumulationin the lungs. To investigate theantiasthmaticpotential of hesperidin aswell asthe underlying mechanism
involved, we studied the inhibitory eﬀect and anti-inﬂammatory eﬀect of hesperidin (HPN) on the production of Th2 cytokines,
eotaxin, IL-17, -OVA-speciﬁc IgE in vivo asthma model mice. Methods. In this paper, BALB/c mice were systemically sensitized to
ovalbumin (OVA) followed intratracheally, intraperitoneally, and by aerosol allergen challenges. Weinvestigated the eﬀect of HPN
on airway hyperresponsiveness, pulmonary eosinophilic inﬁltration, various immune cell phenotypes, Th2 cytokine production
and OVA-speciﬁc IgE production in a mouse model of asthma. Results. In BALB/c mice, we found that HPN-treated groups had
suppressed eosinophil inﬁltration, allergic airway inﬂammation, and AHR, and these occurred by suppressing the production
of IL-5, IL-17, and OVA-speciﬁc IgE. Conclusions. Our data suggest that the therapeutic mechanism by which HPN eﬀectively
treats asthma is based on reductions of Th2 cytokines (IL-5), eotaxin,OVA-speciﬁc IgE production, and eosinophilinﬁltration via
inhibition of GATA-3 transcription factor.
1.Introduction
The features of asthma are airway inﬂammation, reversible
airﬂow obstruction, and an increased sensitivity to bron-
choconstricting agents, termed airway hyperresponsive-
ness (AHR), excess production of Th2 cytokines, and
eosinophil accumulation in the lungs [1]. The immune
cells involved in regulating allergic airway inﬂammatory
responses include monocytes/macrophages, dendritic cells,
neutrophils, basophils, mast cells, eosinophils, T and B
lymphocytes [2]. Moreover, it is well established that there
is a strong interaction between eosinophils and Th2 cells in
the asthmatic airways and that Th2 cell-derived cytokines,
namely IL-4, IL-5, and IL-13, play critical roles in orchestrat-
ing and amplifying allergic inﬂammation in asthma [3].
CD4+ T cells play a crucial role in immune protection,
and they do so through their capacity to help B cells make
antibodies, to recruit neutrophils, eosinophils, and basophils
to sites of inﬂammation, and, through their production
of cytokines and chemokines, to orchestrate the immune
responses [4]. Suppression of cytokine production in acti-
vated CD4+ T cells may be useful for the treatment of
asthma.
Th2 cytokines produced by CD4+ T cells including
interleukin-4 (IL-4), IL-5, and IL-13 enhance immunoglob-
ulin E (IgE) production, eosinophil accumulation, and IL-
13 directly enhances mucus hypersecretion and AHR [5,
6]. Therefore, suppression of Th2 cytokines production in
activated CD4+ Th cells may be useful for the treatment of
inﬂammatory immune diseases including asthma.
Hesperidin (HPN, 5,7,3 -trihydroxy-4 -methoxyﬂavan-
one7-rhamnoglucoside) belongs to the class of ﬂavonoids
called ﬂavanones and is found mainly in citrus fruits and
inhibits proliferation of Ramos cells and sensitizes them to2 Mediators of Inﬂammation
doxorubicin-induced apoptosis through inhibition of both
constitutive and doxorubicin-mediated NF-κBa c t i v a t i o ni n
aP P A R γ-independent manner [7].
Other biological activities of HPN include inhibition
of cell cycle progression in human pancreatic cells [8],
reduction of reactive oxygen species and triggering caspase-
dependent apoptosis in human polymorphonuclear neu-
trophils in vitro [9], cytotoxic eﬀects on human colon
cancer cells, accompanied by DNA fragmentation caspase-
3a c t i v a t i o n[ 10], blood pressure [11], reduction of TNF-
α production [12], anti-inﬂammatory eﬀects on rodent cell
lines and human cell lines [13, 14], an antioxidant eﬀect [15,
16], bone density loss [17], and the reduction of cholesterol
[18].
However, there have beenno reports ofthe antiasthmatic
and anti-inﬂammatory activities of hesperidin in vivo and in
vitro.The aimof thisstudywas toevaluatetheabilityofHPN
to control Th1- and Th2-type cytokines, various immune
cellphenotypes, and otherfactors. Therefore, using a murine
model of asthma, we studied the eﬀect of HPN on airway
eosinophil accumulation, Th2 cytokine production, various
immune cell phenotypes, and histology.
2.Materialsand Methods
2.1. Animals. Five-week-old female BALB/c mice were
obtainedfromDaehanBiolinkCo.LTD.(Eumsung,Republic
of Korea). Our study was approved by the committee for
animal welfare at the institution Daejeon University. More-
over, all animal procedures were conducted in accordance
with the guidelines of the Institutional Animal Care and Use
Committee of the Korea Research Institute of Bioscience and
Biotechnology (Daejeon, Republic of Korea).
2.2. Ovalbumin (OVA) Sensitization and Inhalation. As per
the modiﬁed protocol previously described [19, 20], OVA
(500μgmL −1) in PBS was mixed with equal volumes of 10%
(w/v) aluminum potassium sulfate (alum; Sigma) in distilled
water, then incubated for 60min at RT after adjustment to
pH 6.5 using 10N NaOH, and centrifuged at 750×gf o r
5 minutes. The OVA/alum pellet was resuspended to the
original volume in distilled water. All mice were immunized
on three diﬀerent days (ﬁrst day of 2, 3, 4 weeks before
inhalational exposure) by intraperitoneal (i.p) injections of
0.2mL alum-precipitated antigen containing 100μgo fO V A
(Sigma-Aldrich Korea, Republic of Korea) bound to 4 mg
of aluminum hydroxide (Sigma-Aldrich Korea. Republic of
Korea) in PBS. Seven days after the second sensitization
intratracheally injected with 250μg of OVA (on day 21) on
the back of the tongue, mice were exposed to aerosolized
OVAfor30min/day,3days/weekfor5weeks(ataﬂowrateof
250L/min,1%OVAinnormal salineforﬁrst4weeksand2%
OVAinnormalsalineforlast1week).HPN(5and1mgkg−1,
Sigma-Aldrich Korea, Republic of Korea) and formoterol
(1mgkg−1) in solution form were orally administered 3
times a week for the last 5 weeks. One day after the last OVA
exposures (2% OVA inhalation), airway hyperresponsiveness
was determined and samples (bronchoalveolar lavage ﬂuid,
lung cells, and serum) were collected for further molecular
analyses.
2.3. BALF (Bronchoalveolar Lavage Fluid). Immediately fol-
lowing assessment of AHR, mice were sacriﬁced with an
i.p injection of sodium pentobarbitone (100mgkg−1). The
trachea was cannulated and BAL obtained by washing the
airway lumina. Brieﬂy, cells in the lungs were recovered by
ﬂushing1mLofBALﬂuid(1mMEDTA,10%FBS,PBS)into
the lungs via the trachea. Total cell counts were determined,
and 100μL of ﬂuid was cytospun onto glass slides using
a Cytospin centrifuge (Cellspin, Hanil, Republic of Korea;
400g for 4 minutes). Diﬀerential cell counts were performed
after staining with a Diﬀ-Quik Stain Set (Baxter Healthcare
Corp., Miami, Florida, USA). The supernatant of BALF was
stored at −25◦C for determination of cytokine levels.
2.4. Digestion of Pulmonary Tissue and Cells Preparations.
Single cell suspensions from lung tissues and BALF were
isolated by mechanical disruption in RPMI 1640 medium
supplemented with 2mM L-glutamine, 100U/mL peni-
cillin, 100μgmL −1 streptomycin, 50μM 2-mercaptoethanol,
20mM HEPES, and 2% heat-inactivated fetal bovine serum
(FBS, GIBCO, Grand Island, NY). Brieﬂy, the lungs were
removed from thoracic cavity. After mincing using sterile
scalpels, the tissuewas incubatedinPBS containing 1mg/mL
Collagenase IV and 2mgmL−1 Dispase for 40min at 37◦C
in a sterile polypropylene tube. After incubation, lung tissue
was vigorously pipetted up and down to further dissolve
remaining tissue clumps and then ﬁltered using a 70μm cell-
strainer (Falcon,Le PontdeClaix,France).The totalnumber
of cells was counted manually using a hemocytometer
chamber (Fisher). Between 2 and 4 × 103 cells were spun
ontoglassslides(Cytospincentrifuge,Cellspin,Hanil,Korea;
400gfor4minutes). Diﬀerentialcountswere doneaccording
to standard morphologic criteria.
2.5. Determination of Airway Hyperresponsiveness (AHR).
Airway hyperresponsiveness in mice was estimated using a
previously described method with modiﬁcations [20, 21]. A
Buxco system (Biosystem XA; Buxco Electronics Inc, Troy,
Conn) was used to evaluate the extent of airway constriction
in diﬀerent groups of mice following the protocol described
previously.
P e n hi se q u a lt oP a u s e× PEF/PIF, where Pause = (Te −
Tr)/Tr(PIF,peak inspiratory ﬂow; PEF:peakexpiratory ﬂow;
Te, expiratory time; Tr, relaxation time). In this experiment,
mice were aerosolized with OVA for 30min/day, 3days/week
for 5 weeks. At 24 hours after the ﬁnal inhalation, mice were
given aerosolized normal saline, followed by 3.15, 6.25, 12.5,
25, and 50mg/mL methacholine (Sigma) serially. Airway
reactivity was then monitored for 30 minutes. Diﬀerences of
Penhvaluebetweengroupswereevaluatedusinganunpaired
Student’st-test.
2.6. Hematoxylin-Eosin (H&E), Masson-Trichrome (M-T),
and Periodic Acid-Schiﬀ (PAS) Staining. BALB/c mice were
injected, inhaled, and sprayed with OVA for 5 weeks (threeMediators of Inﬂammation 3
times a week) to induce asthma. Two experimental groups
were treated with diﬀerent concentrations of HPN for the
later 5 weeks (5times/week). At the end of the experiment,
the lungs were removed and analyzed histologically using a
modiﬁed protocol previously described [22].
Brieﬂy,thelungtissuewasembeddedinparaﬃn,thencut
into 3μm thickness sections, stained with H&E solution, M-
T solution. The tissue was subsequently mounted and cover-
slipped with Dako-mounting medium (Dakocytomation;
Denmark Carpinteria CA). The degree of airway inﬂam-
matory cell inﬁltration was scored in a double-blind screen
by two independent. The degree of peribronchiole and
perivascular inﬂammation was evaluated by a subjective
scale of 0–2, as modiﬁed protocol described previously [23].
Periodic acid-Schiﬀ (PAS) stain was performed to identify
mucus secretion in lung tissue. Frozen sections (30mm in
thickness) of each tissue were made. Each sample section
was mounted on the gelatin-coated slide, stained with PAS
reagents, dehydrated, and coverslipped with the permount.
The PAS-positive goblet cells were counted manually and
normalizedtothelengthofthebronchialepithelialperimeter
on the basal side, and expressed as the number of PAS-
positive cells per mm of basement membrane.
2.7. Antibodies and Flow Cytometric Analysis. All antibod-
ies (such as anti-CD3, CD4, CD8, CCR3, CD69, B220,
CD23, CD11b, Gr-1, etc.) for ﬂow cytometric analysis
were purchased from Becton Dickinson (BD) PharMingen
(San Diego, CA). Cells from lung tissues and BALF were
stained with the indicated antibodies in staining buﬀer (PBS
containing 1% FBS and 0.01% NaN3)f o r1 0m i no ni c e ,
and analyzed by two-color ﬂow cytometry on a FACSCalibur
using CellQuest software (BD Biosciences, Mountain View,
CA).
2.8. Enzyme-Linked Immunosorbent Assay (ELISA). Inter-
leukin(IFN-γ,IL-4, IL-5, IL-13,IL-17, eotaxin, etc.)produc-
tion in BALF and anti-OVA IgE in serum of the indicated
mice (n = 5) was measured by ELISA according to the
manufacturer’s instructions with a monoclonal antibody-
based mouse interleukin ELISA kit (R&D system). OVA-
speciﬁc IL-4 and IFN-γ production from spleen cells were
suspended in RPMI 1640 medium supplemented with
2mM L-glutamine, and 5% fetal bovine serum. The spleen
cells were then cultured for 48hrs at a concentration of
1 × 105 cells/well in 96-well culture plates (Corning Inc,
Cambridge, Mass) with or without 1ugmL−1 of OVA in a
humidiﬁedatmosphereof5%CO2 inairat37◦C.Theculture
supernatants were collected and assayed for IFN-γ and IL-4
antibodies induced by OVA using ELISA. All data represent
the mean and standard deviation from at least three separate
determinants andwere comparedusing a analysis of variance
(ANOVA).
2.9. Isolation CD4+ T Cells. As previously described [24],
splenocytes were isolated from naive BALB/c mice. Cells
were enriched for CD4+ cell populations by ﬁrst staining the
cells with anti-CD4 (BD PharMingen, Calif, USA). CD25-
cells were isolated from this population by ﬁrst staining
with ﬂuorescein isothiocyanate- (FITC-) conjugated anti
CD25 mAb (BD PharMingen) followed by incubation with
magnetic-activated cell-sorting anti-FITC beads (Miltenyi
Biotec, Auburn, Calif, USA). CD4+ T cells were selected
on a (CS) column, and the ﬂow-through was collected as
CD4+ T cells. Isolated cells were activated by overnight
incubation on 24-well plates coated with 1μg/mL anti-
CD3 (Serotec.), 1μg/mL anti-CD28 (Serotec.), and with
HPN (10, 1μg/mL) added to RPMI medium supplemented
with 1unit/mL penicillin, 1μg/mL streptomycin, 20Mm L-
glutamine, 50mM-mercaptoethanol, and 5% FBS for 48
hours after stimulation.
2.10. Intracellular Staining for GATA-3and IL-17. For GATA-
3 (PE mouse anti-GATA3; BD Pharmingen), IL-17 (PE-
rat-anti-mouse IL-17; BD Pharmingen) intracellular stain-
ing, isolated CD4+ T cells were stimulated in culture
medium containing rIL-6 (100ng/mL; R&D Systems), TGF-
β (20ng/mL; R&D Systems), and monensin (GolgiStop,
1mL/mL, BD Biosciences) in a cell incubator with 10% CO2
at37◦Cfor4h.Afterstainingsurfacemarkers,cellswereﬁxed
and permeabilized using Cytoﬁx/Cytoperm and Perm/Wash
buﬀer (BD Biosciences) according to the manufacturer’s
instructions.
2.11. Statistical Analysis. Data were analyzed by one-way
analysis of variance (ANOVA) or unpaired Student’s t-
test followed by Dunnett’s multiple comparison test (SPSS
version 14.0 statistic software). The diﬀerence between the
normal group and the control group (OVA + vehicle) was
clearly distinguished, and for this reason, statistical signiﬁ-
cance between the normal group and the control group was
notshown intheﬁguresand tablestoputanemphasis onthe
statistical diﬀerences between the experimental groups and
the control group. Results (presented as mean ± standard
error of mean) were considered statistically signiﬁcant if P
values were <.05 (∗), <.01 (∗∗), or <.001 (∗∗∗).
3.Results
3.1. Inhibitory Eﬀect of HPN on Airway Hyperresponsiveness
(AHR). In order to evaluate the inhibitory eﬀect of HPN
on airway hyperresponsiveness, total pulmonary airﬂow in
mice was estimated using whole-body plethysmography.
PenH was measured using a Buxco system on day 1 after
ﬁnal inhalation, and samples were immediately collected.
Methacholine treatment isuseful to exhibit thedistinct eﬀect
of drugs on Penh value by way of inducing AHR. In OVA-
sensitized and -challenged mice, the dose-response curve of
Penh value was shifted to the left compared with that of
normal mice (Figure 1(b)). As shown in Figure 1(b),r e l a t i v e
to animals sensitized with OVA (control group), AHR to
methacholine was reduced in HPN-treated (5mgkg−1)m i c e
(P<. 01, P<. 05) and formoterol treated mice (P<. 05).4 Mediators of Inﬂammation
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Figure 1: (a) Schematic diagram of methacholine-induced AHR in the sensitization protocol. (b) PenH was measured with a Buxco box,
as described in Materials and Methods. ∗P<. 05, ∗∗P<. 01 for control goup versus HPN-treated groups (c), eﬀect of HPN on histology of
lung tissue (H&E, M-T, and PAS staining) in lung cells of the OVA-induced murine model of asthma. H&E: hematoxylin-eosin stain, M-T:
Masson trichrome stain, PAS: Periodic acid-Schiﬀ stain, N: normal BALB/c mice, CT (control): Ovalbumin inhalation + vehicle, OVA +
formoterol (1mg/kg), OVA + HPN (5, 1mg/kg).Mediators of Inﬂammation 5
However, there was no signiﬁcant diﬀerence between HPN-
treated (1mgkg−1) miceand OVA-sensitized and-challenged
control mice in their methacholine-induced AHR.
3.2. Histological Analysis of Lung Sections. The histopatho-
logical investigation of both OVA-challenged mice and
HPNformoterol-treated miceshowed inﬂammatory changes
when compared with saline-challenged normal mice. Also,
we found inﬁltration of leukocytes in histologic sections
of lungs from OVA-challenged control mice, and lung
tissue sections from OVA-challenged mice showed a dis-
tinct inﬂammatory inﬁltrate and erosion in peribronchial
and perivascular areas. The peribronchial and perivascular
inﬂammatory inﬁltrate consisted of eosinophils and mast
cells, admixed with lymphocytes. Eosinophil inﬁltration
was mainly observed in the peribronchial regions of the
lung. In contrast, histological sections from HPN-treated
mice and formoterol-treated mice indicated reduced airway
inﬂammation in lung tissue (Figure 1(c)).
The degrees of goblet cell hyperplasia and mucus
hyperproduction were evaluated by means of PAS staining
and quantiﬁcation of PAS-stained cells. The OVA-challenged
control mice signiﬁcantly increased the mean numbers of
PAS-positive cells when compared with saline-challenged
normal mice.
In particular, there were greater reduction in the mean
number of PAS-stained goblet cells in the HPN-treated
(5mgkg−1) and formoterol-treated asthma mice than OVA-
sensitized/challenged mice (Figure 1(c)).
3.3. Inhibitory Eﬀect of HPN on Airway Eosinophil Accu-
mulation and Inﬂux of Inﬂammatory Cells into Lung and
BALF. The number oftotal leukocytesin the BALF obtained
from the PBS saline challenged group was 0.95 ± 0.05 × 107
cells, indicating that few eosinophils were detected in this
group. On the other hand, the total number of leukocytes
(2.0±0.1×107) and eosinophils in the BALF cytospin of the
OVA-challengedwas signiﬁcantly higher than thatin thePBS
saline-challenged group.
The total number of leukocytes were signiﬁcantly
reduced in HPN-treated (5mgkg−1) and formoterol-treated
mice compared with control mice, and the number of total
lung cells were also signiﬁcantly reduced in HPN-treated
mice (Figure 2(c)). HPN (5mgkg−1) also decreased the
absolute number of eosinophils in BALF (Figure 2(d)).
3.4. Inhibitory Eﬀect of HPN on Absolute Number of Immune
Cell Subtypes in Murine OVA-Induced Asthma Lung and
BALF. To evaluate the eﬀect of HPN on T cell subtypes ﬂow
cytometric analysis was accomplished. The numbers of CD3,
CD4, CD8, CCR3, CD69,B220, CD23,CD11b, Gr-1 positive
cells in the lungs of OVA-challenged mice were increased
compared to the saline-treated group, and generally, each
values from HPN-treated mice were signiﬁcantly lower
than those of OVA-challenged mice (Table 1). Formoterol
administration resulted in signiﬁcant reduction in T cell
subtypes similarly.
Eﬀects of HPN on leukocyte subsets in lungs and BALF
were markedwith changeinnumbers ofCD3+Tcells, CD4+
helper T cells, Gr-1+/CD11b+ granulocytes, CD3−/CCR3+
eosinophils, CD3+/CCR3+ Th2 cells, CD3+/CD69+ early
activated T cells, B220+/CD23+ B cells in a mouse model
of asthma compared to control group, and the deﬁcits in
CD3−/CCR3+eosinophils were accompanied by concurrent
decreases eosinophils in BALF cytospin (Figure 2(d)).
HPN and formoterol groups treated with OVA resulted
in signiﬁcant reductions in CD3+ T cells (∗∗P<. 01, ∗∗∗P<
.001), Gr-1+/CD11b+ granulocytes (∗∗P<. 01, ∗∗∗P<
.001), B220+/CD23+ B cells (∗P<. 05, ∗∗P<. 01, ∗∗∗P<
.001) in lung were decreased signiﬁcantly and CD3-/CCR3+
(∗∗P<. 01), B220+/CD23+ B cells (∗∗∗P<. 001) in BALF
were also decreased signiﬁcantly (Table 1).
3.5. Inhibition of Th2 Cytokines (In Vivo and In vitro),
Eotaxin, and OVA-Speciﬁc IgE Production in BAL Fluid and
Serum. The eﬀect of HPN and formoterol on Th2 cytokines
and eotaxin protein levels was examined in BALF.
As shown in Figures 3(a) and 3(b), IL-5, IL-17, and
eotaxin levels were signiﬁcantly reduced in HPN-treated
(5mgkg−1) mice. An important component of allergic
asthma model is the production of OVA-speciﬁc IgE.
Therefore, levels of anti-OVA IgE were measured in serum
from the OVA-challenged mice, PBS, formoterol- and HPN-
treated groups. In our study, OVA-speciﬁc IgE levels in
serum from OVA-induced asthmatic mice were signiﬁcantly
increased compared with normal mice (PBS only), and
HPN-treated mice had signiﬁcantly reduced OVA-speciﬁc
IgE (Figure 3(c)). We also measured IL-4, and IFN-γ in the
culture supernatants were measured by ELISA and found
that HPN (5mgkg−1) signiﬁcantly inhibited Th2 cytokine
(IL-4) production in splenocytes (Figure 3(d))w h i c hw a s
accompanied by a concurrent decrease in Th2 cytokine
production in BALF (Figure 3(a)).
3.6. Eﬀect of HPN on Expression of GATA3and IL-17 in CD4+
T cells. As shown in Figure 4, the levels of CD4+/GATA3+,
CD4+/IL-17+ double positive cells in CD4+ T cells were
signiﬁcantly increased in control group (39.5%, 67.7%)
stimulated with anti-CD3, anti-CD28, IL-6, and TGF-β
when compared with that of nonstimulated normal CD4+
T cells (7.4%, 10.9%), and negative control (7.3%, 12.3%).
Following HPN 10, 1μg/mL treatment, there was a decrease
in the number of CD4+/GATA3+ T cell (18.5%, 20.4%) and
CD4+/IL-17+ T cell (50.9%, 51.4%) when compared with
that of the stimulated control group.
4.Discussion
Asthma is characterized by airway obstruction, which is
variable and reversible, and there is chronic inﬂammation
of the respiratory tract, which is mediated by the increased
expression of multiple inﬂammatory proteins, including
cytokines, chemokines, adhesion molecules, inﬂammatory
enzymes, and receptors [25]. Th2 cells and their signature6 Mediators of Inﬂammation
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Figure 2: Eﬀects of HPN on total eosinophils, neutrophils, and basophils in blood and total lung cells, total leucocytes, and eosinophils
in BALF. As described in Section 2, whole blood was harvested 24hrs after the last OVA challenge. Total inﬂammatory cell numbers in
blood were counted, and cell classiﬁcation was performed on a minimum of 200 cells to classify eosinophils and lymphocytes. Results
are expressed as mean ± S.E (N = 5). Statistical signiﬁcance between control and treatment groups was assessed by ANOVA (∗P<. 05,
∗∗P<. 01, ∗∗∗P<. 001). N: normal BALB/c mice, CT: Ovalbumin inhalation+vehicle, formoterol: OVA + formoterol (1mg/kg), OVA +
HPN (5, 1mg/kg).
cytokines IL-4, IL-5, and IL-13 have key pathogenic roles in
asthma [26].
Therapeutic agents that may be used in the treatment of
asthma are numerous. Anti-IL-5 inhibits eosinophil adhe-
sion, inﬁltration, and mediator release [27]. Eosinophilia
is driven by allergen-activated Th2 cells that generate large
amounts of Th2 cytokines (such as IL-4, IL-5, and IL-
13). IL-5 is the most critical cytokine mediating increased
eosinophil diﬀerentiation, activation, and survival [28]. The
recruitment and activation of eosinophils appear to be
controlled by the release of cytokines such as IL-5 and
chemotactic agents such as eotaxin from Ag-stimulated T
lymphocytes [29]. It has been suggested that IL-5 and
eotaxin may collaborate in the regulation of blood and tissue
eosinophilia in mice.
Although the exact mechanism underlying the
biological eﬃcacy of HPN remains elusive, the anti-
inﬂammatory, antioxidant, antidepressant, antimetastatic,
and immunomodulatory eﬀect were reported. However, its
inﬂuence on asthma model has not been studied so far. In
t h ep r e v i o u ss t u d y ,i tw a ss h o w nt h a th e s p e r i d i na tv a r i o u s
dosages ranging from 0.3, 5, and 50mg/kg body weightMediators of Inﬂammation 7
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Figure 3: ((a), (b), (c)) Eﬀect of HPN on Th2 cytokines (IL-5, IL-13), Th17 cytokine (IL-17), eotaxin in BALF, and OVA-speciﬁc IgE in
serum. (d) Immunomodulatory eﬀects of HPN on OVA-speciﬁc Th1/Th2 cytokines production in spleen cells (described in Section 2).
Results are expressed the mean ± S.E (N = 5). Statistical signiﬁcance between control and treatment groups was assessed by ANOVA
(∗P<. 05, ∗∗P<. 01, signiﬁcant increase; #P<. 05). N: normal BALB/c mice, CT: Ovalbumin inhalation+vehicle, formoterol: OVA +
formoterol (1mg/kg), OVA + HPN (5, 1mg/kg).
once daily by i.p injections possessed pharmacological eﬀect
[30]. Moreover, HPN attenuates LPS-induced hepatotoxicity
p o s s i b l yb yp r e v e n t i n gc y t o t o x i ce ﬀects of NO and oxygen
free radicals [31]. In our preliminary study, HPN treatment
(5, 1mgkg−1)d i dn o tc a u s et o x i ce ﬀects on alanine
aminotransferase (ALT) and aspartic acid transaminase
(AST) levels (data not shown). Therefore, we used the above
dose for studying its eﬀect on this model.
Formoterol, given after the allergen challenge, has
a marginal inhibitory eﬀect on the eosinophil inﬂux
and inhibits the allergen-induced airway increased airway
sensitivity to aerosolized methacholine [32]. At present, for-
moterol/budesonide is recommended for use as both main-
tenance and reliever therapy in patients with moderate to
severe asthma [33]. We used it as a positive control which
plays a critical role for immunosuppressants.
Recruitment of eosinophils to the airways is a character-
istic of asthma, and the degree of eosinophilia is correlated
with the severity of this disease. These cells are often
considered to play a major role in inducing airway hyper-
responsiveness (AHR) [34]. Eosinophilic inﬂammation is
regulated to a majorextent by activated T lymphocytesin the
airways thatsecretetheTh2 cytokineIL-5[35].Thiscytokine
is an important mediator in the regulation of eosinophilic8 Mediators of Inﬂammation
Table 1:QuantiﬁcationbymeansofFACS analysisofvariousimmunecell subtypes inlungandBALF.Absolutenumbers ofvariousimmune
cell subtypes in lung were counted (described in Section 2). Results are expressed as mean ± S.E (N = 5). Statistical signiﬁcance between
control and treatment groups was assessed by ANOVA (∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001). N: Normal BALB/c mice, CT: Ovalbumin
inhalation + vehicle, formoterol: OVA + formoterol (1mg/kg), OVA + HPN (5, 1mg/kg).
Cell phenotypes Normal OVA-induced asthma mice (Absolute no.)
in lung and BALF BALB/c Control Formoterol HPN (5mg/kg) HPN (1mg/kg)
CD3+ (×105 cells) 3.43 ± 0.11 9.47 ± 0.52 5.08 ±0.37∗∗∗ 3.10 ±0.59∗∗∗ 6.99 ± 0.41∗∗
CD4+ (×105 cells) 2.03 ± 0.07 7.02 ± 0.77 3.02 ±0.22∗∗ 2.51 ± 0.17∗∗ 5.69 ± 0.79
CD8+ (×105 cells) 0.54 ± 0.03 1.74 ± 0.04 1.34 ± 0.71 0.64 ±0.04∗∗∗ 1.53 ± 0.07
Gr-1+/CD11b+ (×105 cells) 1.45 ± 0.01 4.79 ± 0.38 2.07 ±0.19∗∗ 1.25 ±0.07∗∗∗ 2.01 ± 0.27∗∗
CD3−/CCR3+ (×105 cells) Lung 0.47 ± 0.09 4.49 ± 1.01 2.58±0.22 1.92 ± 0.13∗ 3.01 ± 0.25
CD3+/CCR3+ (×105 cells) 0.17 ± 0.04 1.74 ± 0.10 1.19 ± 0.35 0.91 ± 0.15∗∗ 1.44 ±0.04∗
CD3+/CD69+ (×105 cells) 0.48 ± 0.01 3.68 ± 0.78 1.27 ±0.13∗ 1.42 ± 0.12∗ 2.40 ± 0.82
CD3−/CD19+ (×105 cells) 1.08 ± 0.03 2.89 ± 0.01 1.66 ±0.13∗∗∗ 1.23 ±0.21∗∗∗ 2.37 ± 0.29
B220+/CD13+ (×105 cells) 0.21 ± 0.07 1.76 ± 0.03 0.88 ±0.15∗∗ 0.42 ±0.03∗∗∗ 0.95 ±0.26∗
CD3+ (×103 cells) 0.44 ± 0.11 23.94 ± 0.82 10.72 ±0.60∗∗ 6.88±1.55∗∗ 13.40 ± 4.80
CD4+ (×103 cells) 0.43 ± 0.03 21.23 ± 1.57 9.57 ±0.78∗∗ 7.92 ± 1.65∗∗ 15.69 ± 6.08
CD8+ (×103 cells) 0.06 ± 0.03 2.92 ± 0.60 2.35 ± 0.61 0.85 ± 0.40 1.96 ± 0.53
CD3−/CCR3+ (×103 cells) BALF 0.03 ± 0.02 5.75 ± 1.14 1.62 ±0.01∗∗ 0.53 ± 0.11∗∗ 1.14 ± 0.16∗∗
CD3+/CCR3+ (×103 cells) 0.04 ± 0.01 10.79 ± 1.15 5.18 ±0.44∗∗ 2.11 ± 0.87∗∗ 6.34 ± 1.45
B220+/CD23+ (×103 cells) 0.12 ± 0.01 6.64 ± 0.15 2.65 ±0.51∗∗∗ 0.94 ±0.32∗∗∗ 1.43 ± 0.41∗∗∗
inﬂammation through eﬀects on the proliferation, diﬀeren-
tiation, and activation of eosinophils, as well as providing
a signal for the rapid mobilization of eosinophils from the
bone marrow [36].
HPN prevented the development of AHR (Figure 1(b)),
airway eosinophilia (Table 1), lung inﬂammation
(Figure 1(c)), and decreased Th2 cytokine levels
(Figure 3(a)) in BAL ﬂuid. These results demonstrate that
HPN has profound regulatory eﬀects on the development
of lung allergic responses in the OVA-induced asthma
model. Moreover, the regulatory eﬀects exhibited by HPN
were accompanied by the production of IL-4 in vitro assay
(Figure 3(d)).
Asthma produces immune abnormalities in a wide
variety of cell populations. Thus, another goal in asthma
research includes the evaluation of speciﬁc cell subpopu-
lations. Immunophenotyping by ﬂow cytometry showed a
similar pattern as total lymphocyte numbers in BALF and
lung.
As previously described in results, eﬀects of HPN on
leukocyte subsets in lungs and BALF were marked with
change in numbers of CD3+ T cells, CD4+ helper T cells,
Gr-1+/CD11b+ granulocytes, CD3−/CCR3+ eosinophils,
CD3+/CCR3+ Th2 cells, CD3+/CD69+ early activated T
cells, and B220+/CD23+ B cells in a mouse model of asthma
compared to control group (Table 1), and the deﬁcits in
CD3-/CCR3+ eosinophils were accompanied by concurrent
decreases eosinophils in BALF cytospin (Figure 2(d)). HPN
also inhibits B cell-dependent production of OVA-speciﬁc
IgEin serum(Figure 3(c)),which iscorrelatedwiththeresult
of B220+/CD23+ B cells in lung and BALF.
It was recently suggested that a transient activation-
induced CD69 surface expression may be important for
regulating T cell traﬃcking [37]. Moreover, CD69 might
aﬀect the immune response during T-cell diﬀerentiation,
involving immunoregulatory cytokines that include, but
might not be limited to, TGF-β, which controls T-cell
diﬀerentiation [22].
CC chemokine receptor 3 (CCR3) is expressed on
eosinophils, MC, basophils, and a subset of human Th2-
like T lymphocytes [38]. Eosinophils are attracted, via their
CCR3, in response to chemoattractants such as eotaxin
released in the airways of asthmatics [39]. Inhibition of
pulmonary eosinophilia by blocking the CCR3 receptor with
antagonists may lead to a reduction in the inﬂammation
and the airway responsiveness in asthma. This approach is
investigated by numeral research groups.
Moreover, eosinophils are one of the cell types known to
express Gr-1, therefore eosinophil populations may consti-
tutea substantial portion ofthe CD11b+Gr-1+ populations.
Our results (Table 1) showed that Gr-1+ cells were increased
with OVA challenge but signiﬁcantly decreased with HPN-
treated mice.
Eotaxin is a potent and speciﬁc eosinophil chemoat-
tractant [40] that also activates eosinophils, increasing both
leukotriene C4 synthesis and eosinophil peroxidase activity
[41]. Eotaxin seems to be most important in the early phases
of eosinophil recruitment after allergen challenge [42].
Eotaxin has been previously implicated in allergen-induced
AHR [43]. However, the relationship between eotaxin and
AHR is complex. In many cases, eotaxin caused substantial
airway eosinophilia and in conjunction with IL-5 caused an
even more marked increase in eosinophils.
We observed signiﬁcant correlations between eotaxin,
IL-5 levels, and CCR3 expression on eosinophils. WeMediators of Inﬂammation 9
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(described in Section 2).
hypothesized that HPN and formoterol prevent AHR by
downregulatingeotaxinandIL-5expressionand,insodoing,
by reducing eosinophilia.
A recent study has shown that in a Th2 environment
with a dominance of IL-5, a continuous production of
eosinophils occurs in a mouse model of allergic inﬂamma-
tion [44]. However, the T cell diversity has been expanded
to several subpopulations, including T helper 17 (Th17)
cells, suggesting that the mechanism is more complicated
[45]. Interestingly, cotransfer of Th17 cells with Th2 cells
enhances the expression of eotaxin-1 in the lung, and the
neutralization of eotaxin-1 prior to the inhaled antigen
challenge decreases the eosinophil recruitment into the
airways of the mice transferred with a combination of Th2
cells and Th17 cells [46]. In our result, the mechanism
by which antigen-speciﬁc Th17 cells achieve suppression of
eﬀector T cells is not understood. Therefore, our results do
not give us information about the functional status of the
above cells, that is, Th2 and Th17 cytokine production can
diﬀer because of activation status of some cells. Therefore,
our result can partly explain the reported inhibition about
the Th2 cytokine (IL-5), eotaxin, and IL-17 protein levels. A
possibleexplanationcanbethatineachspeciﬁcmechanisms,
the one or the other population can predominate and
characterize eventually the ﬁnal result.
Commitment of CD4+ Th cells into eﬀector Th2 cells
is controlled by speciﬁc transcription factors GATA-binding
protein 3 (GATA-3). GATA-3 is required for the direct
activation of Th2 cytokines IL-4, IL-5, and IL-13 for Th2 cell
development [47].
Various transcription factors such as c-maf, GATA-3,
NFAT, and STAT6 have been shown to induce or augment
Th2 cytokine production, although only c-maf and GATA-
3 are expressed selectively in Th2 cells [48]. In particular,
GATA-3 has been shown to promote expression of several
Th2 cytokines, including IL-4, IL-5, and IL-13. It is well
known that overexpression of GATA-3 predisposes for Th2-
mediated diseases such as allergic asthma whereas activation
of T-bet appears to be an essential step for Th1-mediated
mucosal diseases such as Crohns, disease. For instance, sup-
pressionofGATA-3expression inthelungwouldpresumably
suppress IL-4, IL-5, and IL-13 production concurrently.
In particular, GATA-3 is important for the expression
of IL-5 in T cells by transactivation of the IL-5 promoter,
b u tG A T A - 3o n l yw e a k l yt r a n s a c t i v a t e st h eI L - 4p r o m o t e r
directly [49].
As shown in Figure 4, the levels of CD4+/GATA3+
double positive cells in CD4+ T cells were signiﬁcantly
decreasedinHPNtreatmentgroup.Itcanbepartlyexplained
that the suppression of GATA-3 expression in the lung
would presumably suppress IL-5 production concurrently.
However, IL-4 productions in vivo (data not shown) and in
vitro was shown diﬀerent pattern. It is unclear why OVA-
speciﬁc IFN-γ production from spleen T cells (Figure 3(d))
was enhanced in GATA-3 inhibited condition, but it is
pos s i bleth a ta ni n cr ea s ei nIFN- γ a l o n em a yn o tb es u ﬃcient
for underexpression of GATA-3 and overexpression of T-bet
simultaneously. This result appears to be partly due to other
signal pathway or more complicated mechanisms involved.10 Mediators of Inﬂammation
GATA-3 and T-bet are essential for cytokine gene activa-
tion during Th1/Th2 diﬀerentiation, but may not be critical
factors in Th1 and Th2 cells. The expression of both T-
bet and GATA-3 mRNAs decreased in the lungs of mice
after repeated antigen challenges. Moreover, the production
of Th1/Th2 cytokines in Th1/Th2 cells may not be directly
regulated by T-bet or GATA-3, because there is a discrepancy
between the expression of T-bet and GATA-3 genes and
Th1/Th2 cytokine levels in the lungs of WT mice after
repeated antigen challenges [50]. T-bet is regulated by IL-
12 via STAT4 and by IL-27 via STAT1. This demonstrates
the complex interplay of cytokines and transcription factors
in asthma [25]. Therefore, our investigation was focused on
Th2 cytokines and GATA-3 transcription factor in this paper.
Although the precise eﬀects of T-bet and GATA-3 in the
pathogenesis of airway remodeling in asthma are still not
fully understood, our ﬁnding of underexpression of GATA-
3 in the airways asthma model mice suggests that HPN has a
signiﬁcant inhibitory role in asthma.
Therefore, HPN may reduce Th2 cytokine (IL-5) pro-
duction and gene expression by inhibition of GATA-3
expression. Our result is not suﬃcient for the explanation
of the precise mechanism, and the mechanism is more
complicated. However, it is a possible mechanism that HPN
shifts immunity from a Th2 to a Th1 bias in a murine model
of asthma. It would be interesting to precisely identify the
complicated mechanisms of our results concerning Th1/Th2
transcription factors in future studies. Moreover, additional
studies are needed to characterize the precise mechanism of
therapeutic action of HPN for treatment of asthma.
5.Conclusions
Our data demonstrate that HPN has profound inhibitory
eﬀects on airway inﬂammation in a mouse model of asthma,
and this eﬀect was caused by suppression of Th2 cytokines
(IL-5), B cell-dependent production of OVA-speciﬁc and
IgE, eosinophil CCR3 expression, through the inhibition
of GATA-3 transcription factor. Hence, HPN may act as a
potential Th2 cytokine (IL-5) antagonist and may have a
therapeutic eﬀect on allergic asthma.
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